

Joseph W Polli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9006465/publications.pdf>

Version: 2024-02-01

51
papers

7,034
citations

101384

36
h-index

174990

52
g-index

55
all docs

55
docs citations

55
times ranked

7039
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug Development Strategy in the United States: An Industrial View of DMPK. <i>Acta Pharmaceutica Hungarica</i> , 2021, 91, 103-105.	0.2	0
2	Mechanistic Basis of Cabotegravirâ€“Glucuronide Disposition in Humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 269-277.	1.3	4
3	Hepatobiliary Disposition of Atovaquone: A Case of Mechanistically Unusual Biliary Clearance. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 366, 37-45.	1.3	1
4	Diseaseâ€“Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 900-915.	2.3	91
5	Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from <i>in vitro</i> studies and a clinical investigation with midazolam. <i>Xenobiotica</i> , 2016, 46, 445-456.	0.5	38
6	Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design. <i>Drug Metabolism and Disposition</i> , 2015, 43, 490-509.	1.7	116
7	Understanding the Transport Properties of Metabolites: Case Studies and Considerations for Drug Development. <i>Drug Metabolism and Disposition</i> , 2014, 42, 650-664.	1.7	53
8	First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. <i>BMC Pharmacology & Toxicology</i> , 2013, 14, 26.	1.0	36
9	Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. <i>BMC Pharmacology & Toxicology</i> , 2013, 14, 25.	1.0	33
10	Central Nervous System Disposition and Metabolism of Fosdevirine (GSK2248761), a Non-Nucleoside Reverse Transcriptase Inhibitor: An LC-MS and Matrix-Assisted Laser Desorption/Ionization Imaging MS Investigation into Central Nervous System Toxicity. <i>Chemical Research in Toxicology</i> , 2013, 26, 241-251.	1.7	67
11	In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor. <i>Drug Metabolism and Disposition</i> , 2013, 41, 353-361.	1.7	201
12	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from <i>in vitro</i> data to clinical study design. <i>Xenobiotica</i> , 2013, 43, 498-508.	0.5	42
13	Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance, and Ketoconazole Interaction Studies. <i>Drug Metabolism and Disposition</i> , 2012, 40, 2090-2101.	1.7	33
14	Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer. <i>Pharmaceutical Research</i> , 2012, 29, 770-781.	1.7	182
15	Assessment of Remogliflozin Etabonate, a Sodium-Dependent Glucose Co-Transporter-2 Inhibitor, as a Perpetrator of Clinical Drug Interactions: A Study on Drug Transporters and Metabolic Enzymes. <i>Journal of Diabetes & Metabolism</i> , 2012, 03, .	0.2	8
16	Response from the International Transporter Consortium. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 75-75.	21.5	5
17	Toxicity and toxicokinetics of metformin in rats. <i>Toxicology and Applied Pharmacology</i> , 2010, 243, 340-347.	1.3	75
18	Oral Sulfasalazine as a Clinical BCRP Probe Substrate: Pharmacokinetic Effects of Genetic Variation (C421A) and Pantoprazole Coadministration. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 1046-1062.	1.6	45

#	ARTICLE	IF	CITATIONS
19	Membrane transporters in drug development. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 215-236.	21.5	2,886
20	If the $K_{1/2}$ Is Defined by the Free Energy of Binding to P-Glycoprotein, Which Kinetic Parameters Define the IC_{50} for the Madin-Darby Canine Kidney II Cell Line Overexpressing Human Multidrug Resistance 1 Confluent Cell Monolayer?. <i>Drug Metabolism and Disposition</i> , 2010, 38, 260-269.	1.7	28
21	Use of cassette dosing in sandwich-cultured rat and human hepatocytes to identify drugs that inhibit bile acid transport. <i>Toxicology in Vitro</i> , 2010, 24, 297-309.	1.1	39
22	An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N -{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({2-(methylsulfonyl)ethyl}amino)methyl]-2-furyl]-4-quinazolinamine}) <i>ETQ00</i>	1.7	246
23	Biopharmaceutics Classification System: Validation and Learnings of an in Vitro Permeability Assay. <i>Molecular Pharmaceutics</i> , 2009, 6, 11-18.	2.3	83
24	The $ABCG2$ C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 233-239.	1.1	41
25	Kinetic Identification of Membrane Transporters That Assist P-glycoprotein-Mediated Transport of Digoxin and Loperamide through a Confluent Monolayer of MDCKII-hMDR1 Cells. <i>Drug Metabolism and Disposition</i> , 2008, 36, 452-460.	1.7	54
26	PhRMA White Paper on ADME Pharmacogenomics. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 849-889.	1.0	62
27	The Role of Efflux and Uptake Transporters in N -{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({2-(methylsulfonyl)ethyl}amino)methyl]-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2008, 36, 695-701.	1.7	226
28	IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES. <i>Drug Metabolism and Disposition</i> , 2006, 34, 786-792.	1.7	256
29	P-Glycoprotein (P-gp) Expressed in a Confluent Monolayer of hMDR1 ⁺ MDCKII Cells Has More Than One Efflux Pathway with Cooperative Binding Sites. <i>Biochemistry</i> , 2006, 45, 15505-15519.	1.2	26
30	The Steady-State Michaelis-Menten Analysis of P-Glycoprotein Mediated Transport Through a Confluent Cell Monolayer Cannot Predict the Correct Michaelis Constant Km. <i>Pharmaceutical Research</i> , 2005, 22, 1667-1677.	1.7	49
31	MULTIPLE MECHANISMS ARE INVOLVED IN THE BILIARY EXCRETION OF ACETAMINOPHEN SULFATE IN THE RAT: ROLE OF MRP2 AND BCRP1. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1158-1165.	1.7	64
32	The Elementary Mass Action Rate Constants of P-gp Transport for a Confluent Monolayer of MDCKII-hMDR1 Cells. <i>Biophysical Journal</i> , 2005, 88, 715-738.	0.2	60
33	Steady-State Brain Concentrations of Antihistamines in Rats. <i>Pharmacology</i> , 2004, 72, 92-98.	0.9	63
34	THE SYSTEMIC EXPOSURE OF AN N-METHYL-D-ASPARTATE RECEPTOR ANTAGONIST IS LIMITED IN MICE BY THE P-GLYCOPROTEIN AND BREAST CANCER RESISTANCE PROTEIN EFFLUX TRANSPORTERS. <i>Drug Metabolism and Disposition</i> , 2004, 32, 722-726.	1.7	29
35	Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 957-968.	1.6	100
36	Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 2108-2123.	1.6	62

#	ARTICLE	IF	CITATIONS
37	In Vitro absorption and secretory quotients: Practical criteria derived from a study of 331 compounds to assess for the impact of P-glycoprotein-mediated efflux on drug candidates. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 2567-2572.	1.6	17
38	Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. <i>Pharmaceutical Research</i> , 2003, 20, 757-764.	1.7	63
39	P-glycoprotein Influences the Brain Concentrations of Cetirizine (Zyrtec®), a Second-Generation Non-Sedating Antihistamine. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 2082-2089.	1.6	76
40	Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 303, 1029-1037.	1.3	567
41	Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial. <i>Pharmacogenetics and Genomics</i> , 2000, 10, 583-590.	5.7	40
42	Influence of passive permeability on apparent P-glycoprotein kinetics. <i>Pharmaceutical Research</i> , 2000, 17, 1456-1460.	1.7	111
43	Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. <i>Pharmaceutical Research</i> , 1999, 16, 1812-1817.	1.7	199
44	Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. <i>Pharmaceutical Research</i> , 1999, 16, 1206-1212.	1.7	205
45	P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells. <i>Biochemical Pharmacology</i> , 1999, 58, 951-957.	2.0	102
46	Expression of the calmodulin-dependent protein phosphatase, calcineurin, in rat brain: developmental patterns and the role of nigrostriatal innervation. <i>Developmental Brain Research</i> , 1991, 63, 105-119.	2.1	74
47	Expression of calmodulin-dependent enzymes in developing rat striatum is not affected by perturbation of dopaminergic systems. <i>Synapse</i> , 1991, 9, 136-143.	0.6	6
48	[53] Identification of calmodulin-binding proteins. <i>Methods in Enzymology</i> , 1990, 184, 451-467.	0.4	20
49	Developmental expression of calmodulin-dependent cyclic nucleotide phosphodiesterase in rat brain. <i>Developmental Brain Research</i> , 1990, 53, 253-263.	2.1	29
50	Developmental expression of neuronal calmodulin-binding proteins in rat brain. <i>Developmental Brain Research</i> , 1990, 53, 62-70.	2.1	9
51	Expression of Calmodulin-Dependent Phosphodiesterase, Calmodulin-Dependent Protein Phosphatase, and Other Calmodulin-Binding Proteins in Human SMS-KCNR Neuroblastoma Cells. <i>Journal of Neurochemistry</i> , 1989, 52, 1438-1448.	2.1	6